Search results for "Eranos"

showing 10 items of 62 documents

Hypoxia-Inducible Factor-1α Activity as a Switch for Glioblastoma Responsiveness to Temozolomide

2018

Rationale: The activity of the transcription factor, hypoxia-inducible factor (HIF)-1?, is a common driver of a number of the pathways involved in the aggressiveness of glioblastomas (GBMs), and it has been suggested that the reduction in this activity observed, soon after the administration of temozolomide (TMZ), can be a biomarker of an early response in GBM models. As HIF-1? is a tightly regulated protein, studying the processes involved in its downregulation could shed new light on the mechanisms underlying GBM sensitivity or resistance to TMZ. Methods: The effect of HIF-1? silencing on cell responsiveness to TMZ was assessed in four genetically different human GBM cell lines by evaluat…

0301 basic medicineCancer Researchapoptosis; chaperone-mediated autophagy activity; hypoxia-inducible factor-1? silencing; temozolomide responsiveness; theranostic biomarkerBiologylcsh:RC254-28203 medical and health scienceshypoxia-inducible factor-1α silencing0302 clinical medicineGliomamedicineGene silencingViability assayTranscription factorOriginal Researchchaperone-mediated autophagy activityTemozolomideAutophagyapoptosismedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenstheranostic biomarker030104 developmental biologyHypoxia-inducible factorsOncologyApoptosis030220 oncology & carcinogenesisCancer researchtemozolomide responsivenessmedicine.drugFrontiers in Oncology
researchProduct

Carbon Nanodots for On Demand Chemophotothermal Therapy Combination to Elicit Necroptosis: Overcoming Apoptosis Resistance in Breast Cancer Cell Lines

2020

Background: Engineered luminescent carbon nanodots (CDs) are appealing nanomaterials for cancer image-guided photothermal therapy combining near infrared (NIR)&ndash

0301 basic medicineCancer ResearchtheranosticsNecroptosisanticancer phototherapynecroptosisSettore BIO/11 - Biologia Molecolare02 engineering and technologylcsh:RC254-282Article03 medical and health sciencesRIPK1breast cancermedicineirinotecan;carbon nanodotsirinotecanChemistrygene expression analysesCancerPhotothermal therapy021001 nanoscience & nanotechnologymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensIrinotecan030104 developmental biologyOncologySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoApoptosisDrug deliveryCancer cellCancer research0210 nano-technologymedicine.drugCancers
researchProduct

Exosomes in cancer theranostic: Diamonds in the rough

2017

IF 3.306; International audience; During the last 10 years, exosomes, which are small vesicles of 50-200 nm diameter of endosomal origin, have aroused a great interest in the scientific and clinical community for their roles in intercellular communication in almost all physiological and pathological processes. Most cells can potentially release these nanovesicles that share with the parent cell a similar lipid bilayer with transmembrane proteins and a panel of enclosed soluble proteins such as heat shock proteins and genetic material, thus acting as potential nanoshuttles of biomarkers. Exosomes surface proteins allow their targeting and capture by recipient cells, while the exosomes' conte…

0301 basic medicineEndosomeReviewexosomes[SDV.BC]Life Sciences [q-bio]/Cellular BiologyBiologyModels BiologicalTheranostic NanomedicineMetastasis03 medical and health sciencesCellular and Molecular NeuroscienceDrug Delivery SystemsNeoplasmsHeat shock proteincancer diagnosisBiomarkers TumormedicineAnimalsHumansTumor microenvironment[ SDV.BC ] Life Sciences [q-bio]/Cellular BiologyCancerCell Biologymedicine.diseasePrimary tumorMicrovesicles3. Good healthCell biology030104 developmental biologyTumor progressionheat shock proteinscancer therapy
researchProduct

The future of Extracellular Vesicles as Theranostics – an ISEV meeting report

2020

ABSTRACT The utilization of extracellular vesicles (EVs) in clinical theranostics has rapidly advanced in the past decade. In November 2018, the International Society for Extracellular Vesicles (ISEV) held a workshop on “EVs in Clinical Theranostic”. Here, we report the conclusions of roundtable discussions on the current advancement in the analysis technologies and we provide some guidelines to researchers in the field to consider the use of EVs in clinical application. The main challenges and the requirements for EV separation and characterization strategies, quality control and clinical investigation were discussed to promote the application of EVs in future clinical studies.

0301 basic medicineEngineeringHistologytheranosticMeeting ReportFreeze thawingExtracellular vesiclesCa 19 9 antigen03 medical and health sciences0302 clinical medicineClinical investigationIn vitro studylcsh:QH573-671therapylcsh:Cytologybusiness.industryDietary intakeAntibody affinityCell BiologyExtracellular vesicles030104 developmental biology030220 oncology & carcinogenesisAntisense oligonucleotidesbiomarkerEngineering ethicsbusinessJournal of Extracellular Vesicles
researchProduct

Evidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine

2016

collaboration au projet H2020 European Cooperation in Science and Technology (COST) program European Network on Microvesicles and Exosomes in Health and Disease (ME-HAD); International audience; Recent research has demonstrated that all body fluids assessed contain substantial amounts of vesicles that range in size from 30 to 1000 nm and that are surrounded by phospholipid membranes containing different membrane microdomains such as lipid rafts and caveolae. The most prominent representatives of these so-called extracellular vesicles (EVs) are nanosized exosomes (70-150 nm), which are derivatives of the endosomal system, and microvesicles (100-1000 nm), which are produced by outward budding…

0301 basic medicineMedical nanotechnologyPhysiologyMedizinGeneral Physics and Astronomyxxx xxxCell CommunicationExosomesRegenerative medicineTheranostic NanomedicineMembrane microparticleEngineering (all)Drug Delivery SystemsPathophysiologicalCell-Derived MicroparticlesCaveolaeDiagnosisGeneral Materials ScienceLipid raftPhospholipidsClinical Trials as TopicPhospholipid membraneVesicleGeneral EngineeringScience and TechnologyEngineering (all); Materials Science (all); Physics and Astronomy (all)3. Good healthCell biologyIntercellular communicationsClinical trial (topic)NanomedicineDrug deliveryRegenerative medicine[SDV.IMM]Life Sciences [q-bio]/ImmunologyNanomedicineMaterials Science (all)HumanEndosomeDrug delivery systemNanotechnologyBiologyProgram diagnosticsPhysics and Astronomy (all)03 medical and health sciencesExtracellular VesiclesAnimalsHumansTherapeutic agentsSettore BIO/16 - Anatomia UmanaAnimalRecent researchesMicrovesiclesCell membranesExosome030104 developmental biologyInternational cooperationMembrane microdomains
researchProduct

Exosomal Chaperones and miRNAs in Gliomagenesis: State-of-Art and Theranostics Perspectives

2018

Gliomas have poor prognosis no matter the treatment applied, remaining an unmet clinical need. As background for a substantial change in this situation, this review will focus on the following points: (i) the steady progress in establishing the role of molecular chaperones in carcinogenesis; (ii) the recent advances in the knowledge of miRNAs in regulating gene expression, including genes involved in carcinogenesis and genes encoding chaperones; and (iii) the findings about exosomes and their cargo released by tumor cells. We would like to trigger a discussion about the involvement of exosomal chaperones and miRNAs in gliomagenesis. Chaperones may be either targets for therapy, due to their…

0301 basic medicineMolecular ChaperoneCellReviewmedicine.disease_causelcsh:ChemistryGene expressiontheranostic toolslcsh:QH301-705.5SpectroscopyChaperone GeneSettore MED/27 - Neurochirurgiamolecular chaperonesGliomaGeneral MedicineHsp60Extracellular MatrixComputer Science ApplicationsCell Transformation Neoplasticmedicine.anatomical_structuregliomas; molecular chaperones; Hsps (Heat shock proteins); Hsp60; miRNA; exosomes; extracellular vesicles; theranostic toolsextracellular vesiclesHumanexosomesBiologyCatalysisInorganic Chemistry03 medical and health sciencesGliomamicroRNAmedicineAnimalsHumansHsps (Heat shock proteins)Physical and Theoretical ChemistryMolecular BiologyGenemiRNAAnimalSettore BIO/16 - Anatomia UmanaOrganic ChemistryBiological Transportmedicine.diseaseMicrovesiclesExosomegliomasMicroRNAs030104 developmental biologylcsh:Biology (General)lcsh:QD1-999Cancer researchextracellular vesicleTheranostic toolCarcinogenesisInternational Journal of Molecular Sciences
researchProduct

Heat shock protein-90 toward theranostics: a breath of fresh air in idiopathic pulmonary fibrosis.

2017

Heat shock proteins are potential biomarkers and therapeutic targets in idiopathic pulmonary fibrosis http://ow.ly/fHVP30hJUOl

0301 basic medicinePulmonary and Respiratory MedicinePathologymedicine.medical_specialtyTheranostic NanomedicinePulmonary FibrosisRespiratory SystemHSP90 Heat-Shock ProteinsTheranostic Nanomedicine03 medical and health sciencesIdiopathic pulmonary fibrosisFresh airHeat shock proteinPulmonary fibrosisMedicineHumansHSP90 Heat-Shock ProteinsRespiratory systemMyofibroblastsHeat-Shock Proteinsbusiness.industrymedicine.diseaseIdiopathic Pulmonary Fibrosis030104 developmental biologyPotential biomarkersbusinessThe European respiratory journal
researchProduct

Exosomal HSP60: a potentially useful biomarker for diagnosis, assessing prognosis, and monitoring response to treatment.

2017

Introduction: Cell-to-cell communication is imperative for life and it is mediated by sending and receiving information via the secretion and subsequent receptor-mediated detection of biological molecules. Exosomes (EXs) secreted from cells to the extracellular environment play an important role in intercellular communication in normal and pathological conditions. Areas covered: New evidence indicates that tumor cells-derived EXs contribute to cancer progression through the modulation of tumor microenvironment. The exosomal heat shock protein 60 (HSP60) is very likely a key player in intercellular cross-talk, particularly during the progress of diseases, such as cancer. Many studies have fo…

0301 basic medicinetheranostic2734BiologyExosomesPathology and Forensic Medicine03 medical and health sciencesExtracellular VesiclesImmune systemHeat shock proteinNeoplasmsGeneticsmedicineBiomarkers TumorAnimalsHumansMolecular Targeted TherapyLiquid biopsyExtracellular Vesicles (EVs)Molecular BiologyCancerTumor microenvironmentLiquid BiopsyExosomes (EXs)CancerChaperonin 60medicine.diseasePrognosisHeat Shock Protein 60 (HSP60)MicrovesiclesBiomarker030104 developmental biologyTreatment OutcomeImmunologyCancer researchMolecular MedicineHSP60BiomarkersExpert review of molecular diagnostics
researchProduct

177Lu-labelled macrocyclic bisphosphonates for targeting bone metastasis in cancer treatment

2016

Background: Metastatic bone lesion is a common syndrome of many cancer diseases in an advanced state. The major symptom is severe pain, spinal cord compression, and pathological fracture, associated with an obvious morbidity. Common treatments including systemic application of bisphosphonate drugs aim on pain reduction and on improving the quality of life of the patient. Particularly, patients with multiple metastatic lesions benefit from bone-targeting therapeutic radiopharmaceuticals. Agents utilizing beta-emitting radionuclides in routine clinical praxis are, for example, [89Sr]SrCl2 and [153Sm]Sm-EDTMP. No-carrier-added (n.c.a.) 177Lu is remarkably suitable for an application in this sc…

<sup>177</sup>LuDO2ABiodistributionDOTABone metastasesBisphosphonateTheranosticsEJNMMI Research
researchProduct

Development of fluorescent platforms for the design of multifunctional compounds for in vitro and in vivo applications in molecular imaging

2018

The objective of this thesis was the development and evaluation of new molecular platformsfor optical fluorescence imaging applications. This work sought to develop new tools that caneasily be modified and adapted to the specific needs of the intended use. This is required asthe fluorophore will influence the final properties and should thus be incorporated beforestructural optimization of the selected agent rather than at the very end. Two main axes wereexplored; the use of BODIPYs for the development of trackable therapeutic agents that areprimarily intended for in vitro applications and the use of azaBODIPYs for the design of an invivo compatible fluorescent platform.In the first part tw…

AzaBODIPYTraçable[SPI.OPTI] Engineering Sciences [physics]/Optics / PhotonicImagerieBodipyTrackable[SPI.OPTI]Engineering Sciences [physics]/Optics / PhotonicTheranostiqueTheranosticsFluorescenceImaging
researchProduct